Viawealth LLC Buys New Position in Johnson & Johnson (NYSE:JNJ)

Key Points

• Viawealth LLC has acquired a new stake in Johnson & Johnson, purchasing 4,544 shares valued at approximately $754,000 during the first quarter.
• Analysts have mixed ratings on Johnson & Johnson, with a consensus rating of "Moderate Buy" and a target price of $174.50, reflecting varying expectations for the company's performance.
• Johnson & Johnson announced a quarterly dividend of $1.30, representing an annualized rate of $5.20 with a yield of 3.13%.

Viawealth LLC bought a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 4,544 shares of the company's stock, valued at approximately $754,000.

Other hedge funds have also recently bought and sold shares of the company. Lantz Financial LLC boosted its stake in shares of Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after buying an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. purchased a new position in Johnson & Johnson in the fourth quarter worth $453,000. Joel Isaacson & Co. LLC boosted its position in Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after purchasing an additional 2,526 shares during the last quarter. State of Wyoming boosted its position in Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after purchasing an additional 10,279 shares during the last quarter. Finally, Range Financial Group LLC boosted its holdings in shares of Johnson & Johnson by 18.9% in the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after buying an additional 2,529 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Guggenheim upped their price target on Johnson & Johnson from $164.00 to $167.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Finally, Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Trading Down 1.3%

Shares of Johnson & Johnson stock opened at $166.18 on Tuesday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a market cap of $399.84 billion, a price-to-earnings ratio of 17.77, a PEG ratio of 2.14 and a beta of 0.41. The company's 50-day moving average price is $156.36 and its 200-day moving average price is $156.14.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the prior year, the company posted $2.82 EPS. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.13%. Johnson & Johnson's payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.